The purpose of the Tissue Analysis and Acquisition Core will be to provide state-of-the-art in situ hybridization and immunohistochemistry support to Investigators participating in the ESDRC. While many of the ongoing, separately funded studies by ESDRC Investigators, as well as those currently proposed in the Pilot and Feasibility Program, will use in vitro models concerning microvascular endothelial cell biology, it will be important to incorporate experiments that address the validity on in vitro observations with in vivo analysis. This Core facility will provide the expertise, training and equipment for the analysis of experimental and archival tissues, and will complement the service and expertise provide through other ESDRC Cores. The Tissue Analysis and Acquisition Core Laboratory will: a) cut tissue sections; b) perform in situ hybridization and/or immunohistochemistry at a reduced cost for members of the Center; c) train individuals to perform in situ hybridization and immunohistochemistry; and d) maintain a tissue bank consisting of clinical specimens and experimental models available for use by Center faculty. Maintenance of a common tissue bank will significantly enhance work in individual labs and improve collaborations between participants in the Center. The addition the in situ hybridization facility will significantly enhance the ability of ESDRC Investigators to analyze experimental models and interpret the in vitro data on microvascular endothelial cells.

Project Start
2002-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
$61,783
Indirect Cost
Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Arbiser, Jack L; Bonner, Michael Y; Gilbert, Linda C (2017) Targeting the duality of cancer. NPJ Precis Oncol 1:
Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit et al. (2017) Peroxisome proliferator-activated receptor gamma (PPAR?) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target EMBO Mol Med 9:508-530
Díaz, Begoña; Ostapoff, Katherine T; Toombs, Jason E et al. (2016) Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget 7:51569-51580
Laidlaw, Kamilla M E; Berhan, Samuel; Liu, Suhu et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget 7:51651-51664
Bhandarkar, Sulochana S; Lanka, Padmavathy; Lanka, Lakshmana Rao et al. (2016) Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions. Exp Dermatol 25:479-80
Costa, Adilson; Bonner, Michael Yi; Arbiser, Jack L (2016) Use of Polyphenolic Compounds in Dermatologic Oncology. Am J Clin Dermatol 17:369-85
Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68
Arbiser, Jack L; Bonner, Michael Y (2016) Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect. J Invest Dermatol 136:564-566
Arbiser, Jack L (2014) PHIPing out: a genetic basis for tumor ulceration. J Invest Dermatol 134:600-602
Spence-Shishido, Allyson; Carr, Christopher; Bonner, Michael Y et al. (2013) In vivo Gram staining of tinea versicolor. JAMA Dermatol 149:991-2

Showing the most recent 10 out of 131 publications